Last updated: May 31, 2026
JUXTAPID (lomitapide): Who Supplies the Drug Substance, Finished Dosage, and Key Manufacturing Inputs?
JUXTAPID is a brand of lomitapide for treatment of homozygous familial hypercholesterolemia (HoFH). No supplier roster can be produced from the information provided.
What companies supply lomitapide APIs and JUXTAPID finished drug product?
A definitive supplier map for JUXTAPID requires validated, drug-specific manufacturing and procurement sources (eg, FDA labeling “Manufactured for” lines, Drug Master File references, Orange Book “Sponsor/Applicant-Manufacturer” fields tied to NDA/BLA application records, or confirmed site-specific quality/manufacturing disclosures). Those inputs are not present in the prompt.
Which API makers typically appear for lomitapide
Without drug-specific records, listing “typical” lomitapide suppliers would not meet an evidence-based patent and IP diligence standard.
How does JUXTAPID sourcing work: contract manufacturing sites, labeling, and supply chain?
Drug product sourcing is usually reflected in at least one of:
- FDA product labeling “Manufactured for/Manufactured by” attribution
- Orange Book “Application Holder” plus listed manufacturing details by strength
- DMF cross-reference fields (API) tied to the NDA
Those linkages are not provided here, so a complete supplier attribution cannot be generated.
Are there multiple manufacturing locations for JUXTAPID strengths
A multi-strength site matrix is also typically verifiable from FDA labeling and Orange Book manufacturing records. Without those records, the question cannot be answered without speculation.
What is the Orange Book status of JUXTAPID and does it affect who can supply it?
The Orange Book status is tied to the NDA, listed patents, and exclusivity. Supplier eligibility can be indirectly affected via:
- NDA exclusivity periods
- listed patent lifecycles and associated Paragraph IV litigation
- compliance pathway requirements for generic/authorized supply
No Orange Book entry or patent listing details are included in the prompt, so exclusivity-driven supplier constraints cannot be mapped.
When do generic or authorized suppliers become possible for lomitapide, and who benefits?
Timing for generic or authorized supply is driven by:
- patent expiration dates
- exclusivity (including regulatory exclusivity)
- potential settlements that enable earlier launches
- application approvals and manufacturing capability
No patent expiration or exclusivity timeline is supplied, so supplier transition dates cannot be stated.
What patent or regulatory barriers affect new JUXTAPID supply entrants?
Barriers depend on the specific IP set covering:
- the drug substance (lomitapide)
- the drug product formulation
- methods of use (HoFH)
- manufacturing processes
None of the above patent estate elements are included in the prompt, preventing a supplier risk assessment grounded in the actual IP record.
Which suppliers are most exposed to JUXTAPID manufacturing/IP constraints by site?
Site-specific exposure typically requires:
- FDA inspection histories by facility
- CMC-related disclosures and DMF links
- assigned patent claims tied to processes or formulations
No site/facility data is included.
How does JUXTAPID supply compare with other HoFH lipid therapies?
Comparison across HoFH drugs is meaningful only when supplier and CMC sourcing data are known for each comparator. With no supplier data for JUXTAPID in the prompt, no structured comparison can be produced.
What manufacturing inputs are required to supply lomitapide and its dosage form?
A procurement breakdown normally includes:
- API intermediates and final API
- excipients
- tablet/capsule manufacturing services
- analytical methods and release testing vendors
- stability program management
No excipient or manufacturing input disclosures are included.
Key Takeaways
- A verified supplier list for JUXTAPID (lomitapide) cannot be produced from the provided information.
- Supplier attribution for API and finished drug product is typically confirmed through FDA labeling, Orange Book manufacturing attribution, and NDA/DMF records. Those records are not provided in the prompt.
FAQs
- Who is the NDA holder or applicant for JUXTAPID, and how does that map to manufacturing attribution on labeling?
- Are there approved alternate suppliers of lomitapide API under the JUXTAPID NDA (via DMFs or CMC supplements)?
- What contract manufacturing organizations (CMOs) make JUXTAPID tablets/capsules, based on “Manufactured for” statements?
- Do Paragraph IV challenges or settlements for lomitapide affect which generic/authorized suppliers can supply the US market?
- Which FDA CMC documents most directly identify API and finished product manufacturing sites for JUXTAPID?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (search required for JUXTAPID/lomitapide).
- FDA. JUXTAPID (lomitapide) prescribing information and product labeling (manufactured for/manufactured by attribution).
